FDA Chief Makary Departs, Cassidy Faces Trump Primary
SkimNews Take
The confluence of an FDA leadership change and a key Senate health committee chair's primary challenge creates unusual uncertainty for the president's health care agenda, which typically relies on stable executive and legislative champions.
Get the Culture newsletter
Daily culture — film, music, books, the trends and ideas worth your attention. Free.
- Lizzy Lawrence discusses Dr. Stephen Makary’s departure from the FDA and the fate of his policies.
- Kyle Diamantas named as acting FDA commissioner after Makary’s exit.
- Chelsea Cirruzzo reports that Senator Bill Cassidy faces two upstart rivals, including a Trump‑backed challenger, in the Senate primary.
- Bill Cassidy confronts a Trump‑backed primary challenger, a result that could shape Trump’s health‑care agenda.
Why it matters: Health‑policy stakeholders gain clarity on FDA direction under Diamantas, while Cassidy’s loss would weaken Senate health leadership and derail Trump’s health‑care reforms and could stall pending drug approvals.
